Fassnacht M - Search Results

1

Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.

Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B; German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors. Fassnacht M, et al. Cancer. 2009 Jan 15;115(2):243-50. doi: 10.1002/cncr.24030. Cancer. 2009. PMID: 19025987 Free article.

2

Adrenal incidentalomas: a manifestation of the metabolic syndrome?

Reincke M, Fassnacht M, Väth S, Mora P, Allolio B. Reincke M, et al. Among authors: fassnacht m. Endocr Res. 1996 Nov;22(4):757-61. doi: 10.1080/07435809609043773. Endocr Res. 1996. PMID: 8969938

3

Aminoglutethimide suppresses adrenocorticotropin receptor expression in the NCI-h295 adrenocortical tumor cell line.

Fassnacht M, Beuschlein F, Vay S, Mora P, Allolio B, Reincke M. Fassnacht M, et al. J Endocrinol. 1998 Oct;159(1):35-42. doi: 10.1677/joe.0.1590035. J Endocrinol. 1998. PMID: 9795339

4

Steroidogenic acute regulatory protein mRNA expression in adrenal tumours.

Zenkert S, Schubert B, Fassnacht M, Beuschlein F, Allolio B, Reincke M. Zenkert S, et al. Among authors: fassnacht m. Eur J Endocrinol. 2000 Mar;142(3):294-9. doi: 10.1530/eje.0.1420294. Eur J Endocrinol. 2000. PMID: 10700725

5

Oral glucose tolerance testing but not intravenous glucose administration uncovers hyper-responsiveness of hypothalamo-pituitary-adrenal axis in patients with adrenal incidentalomas.

Beuschlein F, Borgemeister M, Schirra J, Göke B, Fassnacht M, Arlt W, Allolio B, Reincke M. Beuschlein F, et al. Among authors: fassnacht m. Clin Endocrinol (Oxf). 2000 May;52(5):617-23. doi: 10.1046/j.1365-2265.2000.01006.x. Clin Endocrinol (Oxf). 2000. PMID: 10792342

6

ACTH-receptor expression, regulation and role in adrenocortial tumor formation.

Beuschlein F, Fassnacht M, Klink A, Allolio B, Reincke M. Beuschlein F, et al. Among authors: fassnacht m. Eur J Endocrinol. 2001 Mar;144(3):199-206. doi: 10.1530/eje.0.1440199. Eur J Endocrinol. 2001. PMID: 11248736 Review.

7

New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line.

Fassnacht M, Hahner S, Beuschlein F, Klink A, Reincke M, Allolio B. Fassnacht M, et al. Eur J Clin Invest. 2000 Dec;30 Suppl 3:76-82. doi: 10.1046/j.1365-2362.2000.0300s3076.x. Eur J Clin Invest. 2000. PMID: 11281374 Review.

8

Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity.

Callies F, Fassnacht M, van Vlijmen JC, Koehler I, Huebler D, Seibel MJ, Arlt W, Allolio B. Callies F, et al. Among authors: fassnacht m. J Clin Endocrinol Metab. 2001 May;86(5):1968-72. doi: 10.1210/jcem.86.5.7483. J Clin Endocrinol Metab. 2001. PMID: 11344193 Clinical Trial.

9

Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms.

Schubert B, Fassnacht M, Beuschlein F, Zenkert S, Allolio B, Reincke M. Schubert B, et al. Among authors: fassnacht m. Clin Endocrinol (Oxf). 2001 May;54(5):627-32. doi: 10.1046/j.1365-2265.2001.01253.x. Clin Endocrinol (Oxf). 2001. PMID: 11380493

10

Discerning malignancy in adrenocortical tumors: are molecular markers useful?

Wachenfeld C, Beuschlein F, Zwermann O, Mora P, Fassnacht M, Allolio B, Reincke M. Wachenfeld C, et al. Among authors: fassnacht m. Eur J Endocrinol. 2001 Sep;145(3):335-41. doi: 10.1530/eje.0.1450335. Eur J Endocrinol. 2001. PMID: 11517015

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

460 results

Search Page